Structural optimization of 2,5-thiophene amides as highly potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors for the treatment of osteoporosis

Journal of Medicinal Chemistry

Volumn 56, Issue 1, 2013, Pages 167-181

  Marchais Oberwinkler, Sandrine ^a   Xu, Kuiying ^a   Wetzel, Marie ^a   Perspicace, Enrico ^a   Negri, Matthias ^b   Meyer, Arne ^c   Odermatt, Alex ^c   Möller, Gabriele ^d   Adamski, Jerzy ^d,e   Hartmann, Rolf W ^a,b  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY OF BASEL   (Switzerland)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

11 HYDROXYCORTICOSTEROID; 11 HYDROXYCORTICOSTEROID 1; 11 HYDROXYCORTICOSTEROID 2; 2,5 THIOPHENE AMIDE; AMIDE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; OXIDOREDUCTASE INHIBITOR; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA DEHYDROGENASE 1; TESTOSTERONE 17BETA DEHYDROGENASE 4; TESTOSTERONE 17BETA DEHYDROGENASE 5; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENCY; DRUG STRUCTURE; HAPLORHINI; IC 50; OSTEOPOROSIS;

AMIDES; ANIMALS; BONE DENSITY CONSERVATION AGENTS; CALLITHRIX; CATALYTIC DOMAIN; CELL LINE, TUMOR; CELL-FREE SYSTEM; ENZYME ASSAYS; ESTRADIOL DEHYDROGENASES; HEK293 CELLS; HUMANS; MICE; MICROSOMES; MODELS, MOLECULAR; OSTEOPOROSIS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 84872278810     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3014053     Document Type: Article

References (65)

1. Wu, L.; Einstein, M.; Geissler, W. M.; Chan, H. K.; Elliston, K. O.; Andersson, S. Expression cloning and characterization of human 17 beta-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20 alpha-hydroxysteroid dehydrogenase activity J. Biol. Chem. 1993, 268, 12964-12969
2. Suzuki, T.; Sasano, H.; Andersson, S.; Mason, J. I. 3β- Hydroxysteroid dehydrogenase/Δ5→4-isomerase activity associated with the human 17β-hydroxysteroid dehydrogenase type 2 isoform J. Clin. Endocrinol. Metab. 2000, 85, 3669-3672
3. Bodine, P. V. N.; Komm, B. S. Tissue culture models for studies of hormone and vitamin action in bone cells Vitam. Horm. 2002, 64, 101-151
4. Vanderschueren, D.; Gaytant, J.; Boonen, S.; Venken, K. Androgens and bone Curr. Opin. Endocrinol., Diabetes Obes. 2008, 15, 250-254
5. Vanderschueren, D.; Vandenput, L.; Boonen, S.; Lindberg, M. K.; Bouillon, R.; Ohlsson, C. Androgens and bone Endocr. Rev. 2004, 25, 389-425
6. Cree, M.; Soskolne, C. L.; Belseck, E.; Hornig, J.; McElhaney, J. E.; Brant, R.; Suarez-Almazor, M. Mortality and institutionalization following hip fracture J. Am. Geriatr. Soc. 2000, 48, 283-288
7. McCloskey, E. Effects of third-generation aromatase inhibitors on bone Eur. J. Cancer 2006, 42, 1044-1051
8. Marcus, R.; Wong, M.; Heath, H., 3rd; Stock, J. L. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint Endocr. Rev. 2002, 23, 16-37
9. Orwoll, E.; Ettinger, M.; Weiss, S.; Miller, P.; Kendler, D.; Graham, J.; Adami, S.; Weber, K.; Lorenc, R.; Pietschmann, P.; Vandormael, K.; Lombardi, A. Alendronate for the treatment of osteoporosis in men N. Engl. J. Med. 2000, 343, 604-610
10. Ringe, J. D.; Faber, H.; Farahmand, P.; Dorst, A. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study Rheumatol. Int. 2006, 26, 427-31
11. Ettinger, B.; Black, D. M.; Mitlak, B. H.; Knickerbocker, R. K.; Nickelsen, T.; Genant, H. K.; Christiansen, C.; Delmas, P. D.; Zanchetta, J. R.; Stakkestad, J.; Glüer, C. C.; Krueger, K.; Cohen, F. J.; Eckert, S.; Ensrud, K. E.; Avioli, L. V.; Lips, P.; Cummings, S. R. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA, J. Am. Med. Assoc. 1999, 282, 637-645
12. Felson, D. T.; Zhang, Y.; Hannan, M. T.; Kiel, D. P.; Wilson, P. W.; Anderson, J. J. The effect of postmenopausal estrogen therapy on bone density in elderly women N. Engl. J. Med. 1993, 329, 1141-1146
13. Chen, C.-L.; Weiss, N. S.; Newcomb, P.; Barlow, W.; White, E. Hormone replacement therapy in relation to breast cancer JAMA, J. Am. Med. Assoc. 2002, 287, 734-741
14. Beresford, S. A.; Weiss, N. S.; Voigt, L. F.; McKnight, B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women Lancet 1997, 349, 458-61
15. Grady, D.; Gebretsadik, T.; Kerlikowske, K.; Ernster, V.; Petitti, D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis Obstet. Gynecol. 1995, 85, 304-313
16. Dong, Y.; Qiu, Q. Q.; Debear, J.; Lathrop, W. F.; Bertolini, D. R.; Tamburini, P. P. 17Beta-hydroxysteroid dehydrogenases in human bone cells J. Bone Miner. Res. 1998, 13, 1539-1546
17. Feix, M.; Wolf, L.; Schweikert, H. U. Distribution of 17beta-hydroxysteroid dehydrogenases in human osteoblast-like cells Mol. Cell. Endocrinol. 2001, 171, 163-164
18. Eyre, L. J.; Bland, R.; Bujalska, I. J.; Sheppard, M. C.; Stewart, P. M.; Hewison, M. Characterization of aromatase and 17 beta-hydroxysteroid dehydrogenase expression in rat osteoblastic cells J. Bone Miner. Res. 1998, 13, 996-1004
19. van Grunsven, E G; van Berkel, E.; Ijlst, L.; Vreken, P.; de Klerk, J. B.; Adamski, J.; Lemonde, H.; Clayton, P. T.; Cuebas, D. A.; Wanders, R. J. Peroxisomal d -hydroxyacyl-CoA dehydrogenase deficiency: resolution of the enzyme defect and its molecular basis in bifunctional protein deficiency Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 2128-2133
20. Blomquist, C. H.; Lindemann, N. J.; Hakanson, E. Y. 17 beta-Hydroxysteroid and 20 alpha-hydroxysteroid dehydrogenase activities of human placental microsomes: kinetic evidence for two enzymes differing in substrate specificity Arch. Biochem. Biophys. 1985, 239, 206-215
21. Bydal, P.; Auger, S.; Poirier, D. Inhibition of type 2 17β-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure-activity relationships Steroids 2004, 69, 325-342
22. Poirier, D.; Bydal, P.; Tremblay, M. R.; Sam, K. M.; Luu-The, V. Inhibitors of type II 17beta-hydroxysteroid dehydrogenase Mol. Cell. Endocrinol. 2001, 171, 119-128
23. Sam, K. M.; Auger, S.; Luu-The, V.; Poirier, D. Steroidal spiro-gamma-lactones that inhibit 17 beta-hydroxysteroid dehydrogenase activity in human placental microsomes J. Med. Chem. 1995, 38, 4518-4528
24. Tremblay, M. R.; Luu-The, V.; Leblanc, G.; Noël, P.; Breton, E.; Labrie, F.; Poirier, D. Spironolactone-related inhibitors of type II 17beta-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activities Bioorg. Med. Chem. 1999, 7, 1013-1023
25. Cook, J. H.; Barzya, J.; Brennan, C.; Lowe, D.; Wang, Y.; Redman, A.; Scott, W. J.; Wood, J. E. 4,5-Disubstituted cis-pyrrolidinones as inhibitors of 17β-hydroxysteroid dehydrogenase II. Part 1: Synthetic approach Tetrahedron Lett. 2005, 46, 1525-1528
26. Gunn, D.; Akuche, C.; Baryza, J.; Blue, M.-L.; Brennan, C.; Campbell, A.-M.; Choi, S.; Cook, J.; Conrad, P.; Dixon, B.; Dumas, J.; Ehrlich, P.; Gane, T.; Joe, T.; Johnson, J.; Jordan, J.; Kramss, R.; Liu, P.; Levy, J.; Lowe, D.; McAlexander, I.; Natero, R.; Redman, A. M.; Scott, W.; Seng, T.; Sibley, R.; Wang, M.; Wang, Y.; Wood, J.; Zhang, Z. 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 2. SAR Bioorg. Med. Chem. Lett. 2005, 15, 3053-3057
27. Wood, J.; Bagi, C. M.; Akuche, C.; Bacchiocchi, A.; Baryza, J.; Blue, M.-L.; Brennan, C.; Campbell, A.-M.; Choi, S.; Cook, J. H.; Conrad, P.; Dixon, B. R.; Ehrlich, P. P.; Gane, T.; Gunn, D.; Joe, T.; Johnson, J. S.; Jordan, J.; Kramss, R.; Liu, P.; Levy, J.; Lowe, D. B.; McAlexander, I.; Natero, R.; Redman, A. M.; Scott, W. J.; Town, C.; Wang, M.; Wang, Y.; Zhang, Z. 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidate Bioorg. Med. Chem. Lett. 2006, 16, 4965-4968
28. Wetzel, M.; Marchais-Oberwinkler, S.; Hartmann, R. W. 17β-HSD2 inhibitors for the treatment of osteoporosis: identification of a promising scaffold Bioorg. Med. Chem. 2011, 19, 807-815
29. Wetzel, M.; Marchais-Oberwinkler, S.; Perspicace, E.; Möller, G.; Adamski, J.; Hartmann, R. W. Introduction of an electron withdrawing group on the hydroxyphenylnaphthol scaffold improves the potency of 17β- hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors J. Med. Chem. 2011, 54, 7547-7557
30. Wetzel, M.; Gargano, E. M.; Hinsberger, S.; Marchais-Oberwinkler, S.; Hartmann, R. W. Discovery of a new class of bicyclic substituted hydroxyphenylmethanones as 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors for the treatment of osteoporosis Eur. J. Med. Chem. 2012, 47, 1-17
31. Al-Soud, Y. A.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Synthesis and biological evaluation of phenyl substituted 1 H -1,2,4-triazoles as non-steroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 2 Arch. Pharm. 2012, 345, 610-621
32. Xu, K.; Al-Soud, Y. A.; Wetzel, M.; Hartmann, R. W.; Marchais- Oberwinkler, S. Triazole ring-opening leads to the discovery of potent nonsteroidal 17β-hydroxysteroid dehydrogenase type 2 inhibitors Eur. J. Med. Chem. 2011, 46, 5978-5990
33. Bagi, C. M.; Wood, J.; Wilkie, D.; Dixon, B. Effect of 17beta-hydroxysteroid dehydrogenase type 2 inhibitor on bone strength in ovariectomized cynomolgus monkeys J. Musculoskeletal Neuronal Interact. 2008, 8, 267-280
34. Frotscher, M.; Ziegler, E.; Marchais-Oberwinkler, S.; Kruchten, P.; Neugebauer, A.; Fetzer, L.; Scherer, C.; Müller-Vieira, U.; Messinger, J.; Thole, H.; Hartmann, R. W. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases J. Med. Chem. 2008, 51, 2158-2169
35. Marchais-Oberwinkler, S.; Kruchten, P.; Frotscher, M.; Ziegler, E.; Neugebauer, A.; Bhoga, U.; Bey, E.; Müller-Vieira, U.; Messinger, J.; Thole, H.; Hartmann, R. W. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics J. Med. Chem. 2008, 51, 4685-4698
36. Marchais-Oberwinkler, S.; Wetzel, M.; Ziegler, E.; Kruchten, P.; Werth, R.; Henn, C.; Hartmann, R. W.; Frotscher, M. New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases J. Med. Chem. 2011, 54, 534-547
37. Bey, E.; Marchais-Oberwinkler, S.; Kruchten, P.; Frotscher, M.; Werth, R.; Oster, A.; Algül, O.; Neugebauer, A.; Hartmann, R. W. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases Bioorg. Med. Chem. 2008, 16, 6423-6435
38. Bey, E.; Marchais-Oberwinkler, S.; Werth, R.; Negri, M.; Al-Soud, Y. A.; Kruchten, P.; Oster, A.; Frotscher, M.; Birk, B.; Hartmann, R. W. Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) J. Med. Chem. 2008, 51, 6725-6739
39. Bey, E.; Marchais-Oberwinkler, S.; Negri, M.; Kruchten, P.; Oster, A.; Klein, T.; Spadaro, A.; Werth, R.; Frotscher, M.; Birk, B.; Hartmann, R. W. New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity J. Med. Chem. 2009, 52, 6724-6743
40. Oster, A.; Klein, T.; Werth, R.; Kruchten, P.; Bey, E.; Negri, M.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity Bioorg. Med. Chem. 2010, 18, 3494-3505
41. Oster, A.; Hinsberger, S.; Werth, R.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases J. Med. Chem. 2010, 53, 8176-8186
42. Oster, A.; Klein, T.; Henn, C.; Werth, R.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Bicyclic substituted hydroxyphenylmethanone type inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17 β-HSD1): the role of the bicyclic moiety ChemMedChem 2011, 6, 476-487
43. Spadaro, A.; Negri, M.; Marchais-Oberwinkler, S.; Bey, E.; Frotscher, M. Hydroxybenzothiazoles as new nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) PLoS One 2012, 7, e29252
44. Spadaro, A.; Frotscher, M.; Hartmann, R. W. Optimization of hydroxybenzothiazoles as novel potent and selective inhibitors of 17β-HSD1 J. Med. Chem. 2012, 55, 2469-2473
45. Henn, C.; Einspanier, A.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Lead optimization of 17β-HSD1 inhibitors of the (hydroxyphenyl)naphthol sulfonamide type for the treatment of endometriosis J. Med. Chem. 2012, 55, 3307-3318
46. Qiu, W.; Campbell, R. L.; Gangloff, A.; Dupuis, P.; Boivin, R. P.; Tremblay, M. R.; Poirier, D.; Lin, S.-X. A concerted, rational design of type 1 17beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity FASEB J. 2002, 16, 1829-1831
47. Kruchten, P.; Werth, R.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Development of a biological screening system for the evaluation of highly active and selective 17beta-HSD1-inhibitors as potential therapeutic agents Mol. Cell. Endocrinol. 2009, 301, 154-157
48. Negri, M.; Recanatini, M.; Hartmann, R. W. Computational investigation of the binding mode of bis(hydroxylphenyl)arenes in 17β-HSD1: molecular dynamics simulations, MM-PBSA free energy calculations, and molecular electrostatic potential maps J. Comput.-Aided Mol. Des. 2011, 25, 795-811
49. Zimmermann, J.; Liebl, R.; von Angerer, E. 2,5-Diphenylfuran-based pure antiestrogens with selectivity for the estrogen receptor alpha J. Steroid Biochem. Mol. Biol. 2005, 94, 57-66
50. Schuster, D.; Kowalik, D.; Kirchmair, J.; Laggner, C.; Markt, P.; Aebischer-Gumy, C.; Ströhle, F.; Möller, G.; Wolber, G.; Wilckens, T.; Langer, T.; Odermatt, A.; Adamski, J. Identification of chemically diverse, novel inhibitors of 17β-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening J. Steroid Biochem. Mol. Biol. 2011, 125, 148-161
51. Möller, G.; Deluca, D.; Gege, C.; Rosinus, A.; Kowalik, D.; Peters, O.; Droescher, P.; Elger, W.; Adamski, J.; Hillisch, A. Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and d -homo-estrone Bioorg. Med. Chem. Lett. 2009, 19, 6740-6744
52. Thomas, M. P.; Potter, B. V. L Crystal structures of 11β- hydroxysteroid dehydrogenase type 1 and their use in drug discovery Future Med. Chem. 2011, 3, 367-390
53. Baker, M. E. Unusual evolution of 11beta- and 17beta-hydroxysteroid and retinol dehydrogenases BioEssays 1996, 18, 63-70
54. Kratschmar, D. V.; Vuorinen, A.; Da Cunha, T.; Wolber, G.; Classen-Houben, D.; Doblhoff, O.; Schuster, D.; Odermatt, A. Characterization of activity and binding mode of glycyrrhetinic acid derivatives inhibiting 11β-hydroxysteroid dehydrogenase type 2 J. Steroid Biochem. Mol. Biol. 2011, 125, 129-142
55. Ahasan, M. M.; Hardy, R.; Jones, C.; Kaur, K.; Nanus, D.; Juarez, M.; Morgan, S. A.; Hassan-Smith, Z.; Bénézech, C.; Caamaño, J. H.; Hewison, M.; Lavery, G.; Rabbitt, E. H.; Clark, A. R.; Filer, A.; Buckley, C. D.; Raza, K.; Stewart, P. M.; Cooper, M. S. Inflammatory regulation of glucocorticoid metabolism in mesenchymal stromal cells Arthritis Rheum. 2012, 64, 2404-2413
56. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46, 3-26
57. Denizot, F.; Lang, R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability J. Immunol. Methods 1986, 89, 271-277
58. Pogoda, P.; Priemel, M.; Schilling, A.; Gebauer, M.; Catalá- Lehnenf, P.; Barvencik, F.; Beil, F.; Münch, C.; Rupprecht, M.; Müldner, C.; Rueger, J.; Schinke, T.; Amling, M.; Pogoda, P.; Priemel, M.; Schilling, A.; Gebauer, M.; Catalá-Lehnen, P.; Barvencik, F.; Beil, F.; Munch, C.; Rupprecht, M.; Miildner, C.; Rueger, J.; Schinke, T.; Amling, M. Mouse models in skeletal physiology and osteoporosis: experiences and data on 14839 cases from the Hamburg Mouse Archives J. Bone Miner. Metab. 2005, 23, 97-102
59. Joerg, H.; Holstein, P. G. Mouse Models for the Study of Fracture Healing and Bone Regeneration. In Osteoporosis Research: Animal Models; Duque, G.; Watanabe, K., Eds.; Springer: London, 2011; pp 175-191.
60. Zhu, D. W.; Lee, X.; Breton, R.; Ghosh, D.; Pangborn, W.; Daux, W. L.; Lin, S. X. Crystallization and preliminary X-ray diffraction analysis of the complex of human placental 17 beta-hydroxysteroid dehydrogenase with NADP J. Mol. Biol. 1993, 234, 242-244
61. Jazbutyte, V.; Hu, K.; Kruchten, P.; Bey, E.; Maier, S. K. G.; Fritzemeier, K.-H.; Prelle, K.; Hegele-Hartung, C.; Hartmann, R. W.; Neyses, L.; Ertl, G.; Pelzer, T. Aging reduces the efficacy of estrogen substitution to attenuate cardiac hypertrophy in female spontaneously hypertensive rats Hypertension 2006, 48, 579-586
62. Odermatt, A.; Arnold, P.; Stauffer, A.; Frey, B. M.; Frey, F. J. The N-terminal anchor sequences of 11beta-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane J. Biol. Chem. 1999, 274, 28762-28770
63. Lin, S. X.; Yang, F.; Jin, J. Z.; Breton, R.; Zhu, D. W.; Luu-The, V.; Labrie, F. Subunit identity of the dimeric 17 beta-hydroxysteroid dehydrogenase from human placenta J. Biol. Chem. 1992, 267, 16182-16187
64. Sam, K. M.; Boivin, R. P.; Tremblay, M. R.; Auger, S.; Poirier, D. C16 and C17 derivatives of estradiol as inhibitors of 17 beta-hydroxysteroid dehydrogenase type 1: chemical synthesis and structure-activity relationships Drug Des. Discovery 1998, 15, 157-180
65. Day, J. M.; Tutill, H. J.; Newman, S. P.; Purohit, A.; Lawrence, H. R.; Vicker, N.; Potter, B. V. L; Reed, M. J. 17Beta-hydroxysteroid dehydrogenase type 1 and type 2: association between mRNA expression and activity in cell lines Mol. Cell. Endocrinol. 2006, 248, 246-249